Pneumocystis jirovecii pneumonia in diffuse large B‐cell Lymphoma treated with R‐CHOP

Background The aim of this study was to estimate the incidence of and risk factors for Pneumocystis pneumonia (PCP) infection in diffuse large B‐cell lymphoma (DLBCL) patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP). Methods The medical records...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Mycoses 2021-01, Vol.64 (1), p.60-65
Hauptverfasser:	Lee, Ji Yun, Kang, Minsu, Suh, Koung Jin, Kim, Ji‐Won, Kim, Se Hyun, Kim, Jin Won, Kim, Yu Jung, Song, Kyoung‐Ho, Kim, Eu Suk, Kim, Hong Bin, Lee, Keun‐Wook, Kim, Jee Hyun, Bang, Soo‐Mee, Lee, Jong‐Seok, Lee, Jeong‐Ok
Format:	Artikel
Sprache:	eng
Schlagworte:	B-cell lymphoma Cyclophosphamide Doxorubicin incidence L-Lactate dehydrogenase Lactic acid Lymphoma Medical records Monoclonal antibodies mortality Patients Pneumocystis pneumonia Pneumonia Prednisone Prophylaxis Risk factors Rituximab R‐CHOP Targeted cancer therapy trimethoprim‐sulfamethoxazole Vincristine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!